The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious
Diseases Society of America jointly sponsored the development of this guideline for the …

On May 19, 2014, the 67th World Health Assembly (WHA) adopted WHO’s “Global strategy
and targets for tuberculosis prevention, care and control after 2015”. 1 This post-2015 global …

Latent tuberculosis infection (LTBI) is characterised by the presence of immune responses
to previously acquired Mycobacterium tuberculosis infection without clinical evidence of …

Background Shortening the course of treatment for tuberculosis would be a major improvement
for case management and disease control. This phase 3 trial assessed the efficacy and …

Toll-like receptors (TLRs) and members of their signaling pathway are important in the
initiation of the innate immune response to a wide variety of pathogens 1 , 2 , 3 . The adaptor …

Drugs for tuberculosis are inadequate to address the many inherent and emerging
challenges of treatment. In the past decade, ten compounds have progressed into the clinical …

We combined two tuberculosis genome-wide association studies from Ghana and The Gambia
with subsequent replication in a combined 11,425 individuals. rs4331426, located in a …

Antimicrobial resistance is a major global concern. Tuberculosis (TB) strains resistant to
rifampicin and other TB medicines challenge patient survival and public health. The World …

SETTING: Current treatment for pulmonary tuberculosis (TB) might be shortened by the
incorporation of fluoroquinolones (FQs).OBJECTIVES: A Phase II study aimed to assess the …

Tuberculosis is still one of the most important causes of death worldwide. The 2010 Lancet
tuberculosis series provided a comprehensive overview of global control efforts and …